H2AC14是一种新的,可靠的CRC预后标志物
Min Luo1,2, Yue Zhang1, Pei-Feng Li1
1Institute for Translational Medicine, Qingdao University, Qingdao, China.
Medicine
|January 10, 2026
概括
基因组群2 H2A家族成员C14 (H2AC14) 在结直肠癌 (CRC) 中过度表达,并促进瘤转移. 这表明H2AC14可能作为CRC的诊断生物标志物,有助于治疗和预后.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
背景情况:
- 结肠直肠癌 (CRC) 的发病率和死亡率正在上升,需要新的生物标志物用于预后和治疗.
- 基因组群2 H2A家族成员C14 (H2AC14) 是一种基因组蛋白,在CRC中起着尚未探索的作用.
研究的目的:
- 研究H2AC14在结直肠癌 (CRC) 进展,诊断和预后方面的潜在作用.
- 探索H2AC14作为CRC的潜在诊断生物标志物.
主要方法:
- 使用癌症基因组图谱-结肠腺癌数据库进行生物信息学分析.
- 在CRC细胞系 (LOVO,HT29,HCT116,SW480) 和正常结肠细胞 (NCM460) 中进行基因表达分析.
- 基因沉默实验,以评估H2AC14在细胞迁移和上皮-介质细胞转换 (EMT) 中的功能作用.
主要成果:
- 与正常组织相比,H2AC14在CRC组织中显著过度表达.
- 在CRC患者中,H2AC14表达与TNM分期,预后和整体存活率相关.
- 沉默H2AC14减少了CRC细胞迁移和下调EMT相关基因,表明H2AC14促进转移.
- 曲线分析下的面积证实了H2AC14对CRC的诊断预测价值.
结论:
- 在结直肠癌中,H2AC14被上调调节,通过促进表皮-介质细胞过渡过程,促进瘤转移.
- H2AC14显示出作为CRC的诊断生物标志物的潜力.
- 需要进一步的临床研究来探索H2AC14在CRC中的治疗和预后影响.
相关概念视频
02:39lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
01:12Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...